Predicting malignancy in mediastinal lymph nodes by endobronchial ultrasound: A new ultrasound scoring system
Gerald Schmid‐Bindert(Heidelberg University), Lothar R. Pilz(Heidelberg University), Caicun Zhou(Tongji University), Hao Wang, Thomas Henzler(Heidelberg University), Hongbin Jiang, Shengxiang Ren(Tongji University), Georg Kähler, Joachim Saur(University of Cologne)
Cited by 66
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504